StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)

StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Free Report) in a research note published on Wednesday. The brokerage issued a hold rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Price Performance Shares of CYCC opened at $2.28 on Wednesday. The business has a 50-day moving average of $2.31 and a 200 day […]

Leave a Reply

Your email address will not be published.

Previous post Power and Torque: 7 Diesel Truck Performance Upgrades You Need to Know
Next post Cytosorbents (NASDAQ:CTSO) Receives New Coverage from Analysts at StockNews.com